Literature DB >> 26272554

Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLR-2 agonist Pam₂Cys.

Edin J Mifsud1, Amabel C L Tan1, Patrick C Reading1,2, David C Jackson1.   

Abstract

We have previously shown that intranasal administration of the Toll-like receptor-2 agonist, S-(2,3-bis(palmitoyloxy)propyl) cysteine (Pam2Cys), provides immediate and antigen independent protection against challenge with influenza virus. Here we characterize the cellular pulmonary environments of mice which had either been treated with Pam2Cys or placebo and then challenged with influenza virus. We show that Pam2Cys treatment results in the influx of innate immune cells into the lungs and that depletion of phagocytic cells from this influx using clodronate-loaded liposomes caused a reduction in the number of interstitial macrophages and monocytes. This resulted in abolition of the protective effect indicating the importance of this cellular subset in Pam2Cys-mediated protection.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26272554     DOI: 10.1038/icb.2015.81

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  46 in total

Review 1.  Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders.

Authors:  Malkeet Singh Bahia; Maninder Kaur; Pragati Silakari; Om Silakari
Journal:  Cell Signal       Date:  2015-02-27       Impact factor: 4.315

2.  Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice.

Authors:  Yumi Hashimoto; Takeshi Moki; Takenori Takizawa; Akiko Shiratsuchi; Yoshinobu Nakanishi
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

3.  Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens.

Authors:  G A Tannock; J A Paul; R D Barry
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

4.  Involvement of the mannose receptor in infection of macrophages by influenza virus.

Authors:  P C Reading; J L Miller; E M Anders
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus.

Authors:  T C Dawson; M A Beck; W A Kuziel; F Henderson; N Maeda
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 6.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications.

Authors:  N Van Rooijen; A Sanders
Journal:  J Immunol Methods       Date:  1994-09-14       Impact factor: 2.303

7.  Interaction of influenza virus with mouse macrophages.

Authors:  B Rodgers; C A Mims
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

8.  CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality.

Authors:  Kaifeng Lisa Lin; Yasushi Suzuki; Hideki Nakano; Elizabeth Ramsburg; Michael Dee Gunn
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

9.  Reprogramming of murine macrophages through TLR2 confers viral resistance via TRAF3-mediated, enhanced interferon production.

Authors:  Darren J Perkins; Swamy K Polumuri; Meghan E Pennini; Wendy Lai; Ping Xie; Stefanie N Vogel
Journal:  PLoS Pathog       Date:  2013-07-11       Impact factor: 6.823

10.  Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.

Authors:  Elizabeth B Norton; John D Clements; Thomas G Voss; Lucia Cárdenas-Freytag
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

View more
  3 in total

1.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

Review 2.  Prospects on Repurposing a Live Attenuated Vaccine for the Control of Unrelated Infections.

Authors:  Sang-Uk Seo; Baik-Lin Seong
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

3.  The Toll-Like Receptor 2 agonist PEG-Pam2Cys as an immunochemoprophylactic and immunochemotherapeutic against the liver and transmission stages of malaria parasites.

Authors:  Medard Ernest; Carol Hunja; Yuka Arakura; Yohei Haraga; Hussein M Abkallo; Weiguang Zeng; David C Jackson; Brendon Chua; Richard Culleton
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-10-23       Impact factor: 4.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.